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Abstract 
In this study we analyzed Spanish Post-Heart-Transplant Tumour Registry data for adult heart transplantation (HT) 
patients since 1984. Median post-HT follow-up of 4357 patients was 6.7 years. Lung cancer (mainly squamous cell or 
adenocarcinoma) was diagnosed in 102 (14.0% of patients developing cancers) a mean 6.4 years post-HT. Incidence 
increased with age at HT from 149 per 100 000 person-years among under-45s to 542 among over-64s; was 4.6 times 
greater among men than women; and was four times greater among pre-HT smokers (2169 patients) than nonsmokers 
(2188). The incidence rates in age-at-diagnosis groups with more than one case were significantly greater than 
GLOBOCAN 2002 estimates for the general Spanish population, and comparison with published data on smoking 
and lung cancer in the general population suggests that this increase was not due to a greater prevalence of smokers 
or former smokers among HT patients. Curative surgery, performed in 21 of the 28 operable cases, increased Kaplan–
Meier 2−year survival to 70% versus 16% among inoperable patients. 
Abbreviations: HT, heart transplantation; SPHTTR, Spanish Post-Heart-Transplant Tumour Registry; NCNL, 
noncutaneous nonlymphomatous; Cis, confidence intervals; SIRs, standard incidence rates; Pys, person-years; NOS, 
not otherwise specified; ASR, age-standardized overall rates 
Introduction 
In the world as a whole, lung cancer is the commonest malignancy bar breast or prostate cancer; in 
Europe it is the commonest bar these and colorectal cancer, and estimates for Spain show the same 
situation (1). Among patients who have undergone heart transplantation (HT), lung cancer is the second 
commonest malignancy, approximately ex aequo with lymphomas and behind skin cancers, which 
account for about 50% of the total (2,3). Whereas it is well attested that the incidence of lymphoma and 
skin cancer among HT patients is higher than in the general population (see, for example, Jensen et al. 
(4); Swerdlow et al. (5); Roithmaier et al. (6)), studies of post-HT lung cancer have produced discrepant 
results in this regard (6–9). 
The Spanish Post-Heart-Transplant Tumour Registry (SPHTTR) continually updates data on tumors 
in all patients who have undergone HT in Spain since the initiation of HT in this country in 1984. Here 
we report on an analysis of SPHTTR data for adult post-HT lung cancer with regard to its incidence 
(overall and among various patient subgroups), its characteristics, the treatment given and survival. 
Methods 
The SPHTTR contains records for 5301 patients who underwent HT in Spain between 1984 and the 
end of 2008 when aged > 15 years. Of these, we excluded from this study 942 who died within 3 months 
of HT and two who underwent HT on December 31 2008. Of the 4357 included, 3648 (83.7%) were men 
aged 51.8 ± 10.9 years at HT and 709 women aged 50.2 ± 12.3 years at HT. 
For determination of the incidence of lung cancer in various groups, the data considered were sex, age 
at HT, age at diagnosis of lung cancer, pre-HT smoking history, development of any tumor, development 
of a noncutaneous nonlymphomatous (NCNL) tumor, development of lung cancer and duration of follow-
up (terminated at the earlier of death or December 31st 2008). For characterization of post-HT lung 
cancer, additional variables considered were the time between HT and diagnosis, the histopathological 
characteristics of the tumor, whether it was disseminated or localized at diagnosis, surgery (curative, 
palliative or none) and postdiagnosis survival. 
Total incidence (age-standardized for the world standard population aged > 15 years (10)), and 
incidence in age-at-diagnosis groups (16–44, 45–54, 55–64 and ≥ 65 years), were compared with 
GLOBOCAN 2002 estimates for the general Spanish population (11). The discrepancy between the age 
of initiation of adulthood used in the SPHTTR (16 years) and the lower limit of the 15–44 years age 
group used for the world standard population is deemed of no consequence in this study. Confidence 
intervals (CIs) for incidence rates in HT patient age groups were calculated using the quadratic 
approximation to the Poisson log likelihood for the log rate parameter (12). CIs for GLOBOCAN 2002 
age-group-specific incidence rate estimates, and the statistical significance of rate ratios, were calculated 
as described by Rosner (13) using Epidat 3.1 (14). CIs for age-standardized overall incidence rates were 
calculated as per Fay and Feuer (15) using Epidat 3.1. 
Incidence was related to age at HT by means of a Poisson regression analysis. Postdiagnosis survival 
curves were constructed by the Kaplan–Meier method and were compared using log rank tests to estimate 
the statistical significance of differences. 
Except where otherwise stated, all statistical calculations were performed using Stata v10.0. 
This research protocol was approved by the institutional review board of each participating center. 
Results 
Total follow-up of the patients included in the study was 26 989.6 person-years (pys) for the 3648 men 
(median individual follow-up time 6.8 years), and 5044.0 pys for the 709 women (median 6.5 years). Of 
all 4357 patients, 729 (16.7%) developed 997 tumors, of which 103 (10.3%) in 102 patients (14.0% of 
patients developing cancers, 2.3% of all patients) were lung cancers. Lung cancers constituted 25.8% of 
all NCNL malignancies. In what follows, only the first of the lung tumors developed by the patient who 
developed two is considered in the analyses. 
Ninety-eight of the 102 patients with lung cancer (96%) were men. Among all 102, age at HT ranged 
from 37 to 72 years (mean 55.3, SD 7.9 years), with twelve patients aged < 45 years, thirty 45–54 years, 
fifty 55–64 years and ten ≥ 65 years. Eighty of the 102 (78%) had a pre-HT history of smoking; 11 had 
previously developed other post-HT tumors (which for 9 of the 11 included cancers of the skin, including 
one case of melanoma); and four developed other primary cancers following the appearance of lung 
cancer (all four NCNL tumors). 
The incidence among male patients was 4.6 times that among women, 363.1 per 100 000 pys as 
against 79.3 (p < 0.001); see Table 1. Incidence increased with age at HT at a compound rate of almost 
5% per year (incidence rate ratio 1.0469, p < 0.001), from an average 149 per 100 000 pys among under-
45s to 542 among over-64s. Among men, incidence increased with age at diagnosis, but the rate ratio 
relative to the corresponding GLOBOCAN 2002 estimate for the general Spanish population fell from 4.5 
for under-45s to 1.8 for over-64s, although these ratios were statistically significant (p ≤ 0.0002) for all 
groups other than the under-45s (in which group only one case of lung cancer occurred); the age-
standardized rate ratio was 2.18 (Figure 1). The small number of cases among women limited the 
accuracy of rate and rate ratio estimates, but even so the rate ratio for the 55–64 year age group, 8.4, was 
statistically significant (p < 0.05). 
Table 1.  Incidence of lung cancer per 100 000 person-years among heart transplantation patients and 
subgroups defined by sex, age at transplantation or pretransplantation smoking behavior, with incidence 
rate ratios or relative risk where appropriate and 95% confidence intervals in parentheses.  
Table 1.  Incidence of lung cancer per 100 000 person-years among heart transplantation patients and subgroups defined by sex, age 
at transplantation or pretransplantation smoking behavior, with incidence rate ratios or relative risk where appropriate and 95% 
confidence intervals in parentheses 
Group Follow-up (person-years) Cases Incidence rate Relative risk p 
      
Total 32 034 102 318 (262–387) – – 
Sex      
 Male 26 900  98 363 (298–443) 4.58 (1.69–12.44) <0.001 
 Female  5044   4  79 (30–211) 1  
Age at HT (years)      
 <45  8040  12 149 (85–263) 1   
 45–54  9750  30 308 (215–440) 2.06 (1.06–4.03) 0.03 
 55–64 12 397  50 403 (306–532) 2.70 (1.44–5.07) <0.001 
 ≥65  1846  10 542 (291–1007) 3.63 (1.57–8.40) <0.001 
Pre-HT smoking      
 No 16 800  22 131 (86–199) 1   
 Yes 15 233  80 525 (422–654) 4.01 (2.50–6.43) <0.001 





Figure 1. Incidence rates per 100 000 person-years in successive age-at-diagnosis groups, and age-standardized overall rates (ASR), 
for lung cancer among heart transplantation patients (SPHTTR data) and for the general Spanish population (GLOBOCAN 2002 
estimates). Whiskers show 95% confidence intervals. Top, men; bottom, women.  
The numbers of pre-HT smokers and nonsmokers among the 4357 patients were very similar, 2169 
and 2188, respectively. However, with an incidence of 525 per 100 000 pys, pre-HT smokers were four 
times more likely to develop lung cancer than nonsmokers (incidence 131 per 100 000 pys). 
The mean time between HT and diagnosis of lung cancer was 6.4 years (SD 3.7 years, median 5.7 
years). At diagnosis, the cancer was disseminated in 79 of the 100 patients for whom information on 
dissemination status was available, and the main broad histopathological types were squamous cell 
carcinoma and adenocarcinoma (Table 2). Curative surgery was attempted in 21% of cases, palliative 
surgery was performed in 7% and 72% were deemed unfit for surgery. 
Table 2.  Characteristics of lung cancer at diagnosis 
  
Mean (SD) time since transplantation (years) 6.36 (3.72) 
Extent*  
 Localized 21 
 Disseminated 79 
Surgery*  
 None 72 
 Palliative  7 
 Curative 21 
Histology**  
 Epidermoid carcinoma NOS*** 28 
 Adenocarcinoma NOS*** 22 
 Carcinoma NOS*** 24 
 Oat-cell carcinoma (high-grade neuroendocrine carcinoma)  4 
 Non-Hodgkin lymphoma  3 
 Carcinoid (low-grade neuroendocrine carcinoma)  1 
 Sarcoma  1 
 T cell lymphoma  1 
 Not available 15 
  
 
*Out of 100 patients for whom relevant data were available. 
**Out of 99 patients for whom relevant data were available. 
***NOS, not otherwise specified. 
Overall Kaplan–Meier survival fell to 26% within 2 years of diagnosis, and 16% after 5 years. There 
were no statistically significant differences between the survival curves of men and women, or between 
those of over- and under-55s, or between those of pre−HT smokers and nonsmokers. However, there was 
a significant difference among the curative surgery, palliative surgery and no surgery groups (p = 0.0004), 
the curative surgery group having a Kaplan–Meier 2-year survival rate of 70% as against 16% in the no-




Figure 2. Kaplan–Meier estimates of intrinsic survival rates among HT patients following diagnosis of post-HT lung cancer. (p = 
0.0004).  
Discussion 
In this study we found the incidence of lung cancer to be considerably greater among Spanish HT patients 
than corresponded to GLOBOCAN 2002 estimates for the general Spanish population. Assuming Poisson 
distributions for cases, the difference was statistically significant in all age-at-diagnosis groups in which 
more than one case was recorded among HT patients. Although the way in which the GLOBOCAN 
estimates were constructed doubtless endowed them with a degree of uncertainty over and above the error 
due to finite sampling, the observed differences, together with the CIs for the incidence rates among HT 
patients (Figure 1), strongly suggest that the risk of lung cancer is greater among HT patients than in the 
general population, especially in view of the between-age-group consistency in the sign of the difference. 
Similar conclusions have previously been reached by Serraino et al. (9) in northern and central Italy, 
Jiang et al. (8) in Canada and Collet et al. (16) in the United Kingdom; these authors observed incidence 
rates among HT patients to be 2.1–2.8 times greater than in the general population. By contrast, a study at 
Columbia Presbyterian Hospital, New York, found no significant difference between the HT and general 
populations in regard to the incidence of lung cancer (7). A possible cause of this discrepancy would 
seem to be Kellerman et al.'s use of a reference population that may have been inappropriate for their HT 
population. The finding that the incidence of lung cancer is higher among HT patients than in the general 
population brings this cancer into line with skin cancer (4) and lymphoma (5), and at the same time brings 
HT patients into line with other solid organ transplant patients (16,17). 
Skin cancer was among the post-HT cancers developed by 9 of the 11 patients with post-HT cancers 
prior to their lung cancer. This finding is in keeping with the known high incidence of skin cancers among 
HT patients (2,18). 
It has been suggested that the high incidence of lung cancer among HT patients—especially in 
comparison with other cancers without known viral associations—may be largely due to a large 
proportion of HTs being motivated by cardiopathologies that like lung cancer are favored by smoking, so 
that HT patients constitute, a priori, a population at especially high risk for lung cancer (7,19–21). 
However, in this study there were marginally fewer pre−HT smokers than nonsmokers, even though 84% 
of HT patients were men; for this proportion of males, some 62% of patients would be expected to be 
sometime smokers on the basis of data for the general population of 2001 (22), and probably a larger 
percentage for earlier years, given the trend for fewer men and more women to be smokers (23). 
Furthermore, in this study the incidence of lung cancer was only four times greater among pre-HT 
smokers than among nonsmokers, a relative risk that in the general populations of western nations seems 
only to be achieved a dozen or more years after cessation of smoking (24,25). It therefore seems likely 
that in this study the group of pre-HT smokers actually reduced the average risk of HT patients relative to 
the general population—probably because, as the observed 4:1 ratio suggests, as patients with advanced 
heart failure they will have ceased smoking several years before HT. We have no information on possible 
post-HT smoking, but since it would in all probability have tended to inflate the incidence of lung cancer 
among self-proclaimed former smokers, it would play in favour of our conclusion. Taken together, the 
above findings thus indicate that although pre-HT smoking certainly increases the risk of lung cancer, as 
would be expected, the extra risk of HT patients as a class (relative to the general population) is not due to 
smoking-related bias but has HT-related causes, probably immunosuppression. 
That incidence increased with age at HT and with age at diagnosis was to be expected in view of the 
known age-dependence of the incidence of lung cancer in the general population. However, the incidence 
rate ratio between the HT and general populations fell with increasing age, the cause of which trend is not 
clear. One possibility is that, with increasing age, the effect of immunosuppression becomes relatively 
less due to the gradual decline of the immune system in normal aging. 
The mean time between HT and diagnosis of lung cancer, 6.4 years, was similar to the 74 months 
observed by Bruschi et al. (26) and the 69 months reported by Mohammadi et al. (27), although the 
median time, 5.7 years, was somewhat shorter than the 7.4 years reported by Anyanwu et al. (21). 
Although the only cancer staging information included in the SPHTTR is the distinction between 
localized and disseminated tumors and the indirect information provided by decisions on surgery, our 
findings also seem to agree with those of Bruschi et al. (26) and others (19,21) as regards lung cancer 
having frequently been detected only at an advanced stage. Pre−HT smoking had no significant influence 
on either the median time between HT and diagnosis (pre-HT smokers 5.6 years, nonsmokers 6.0 years) 
or the proportion of patients who were unfit for curative surgery at diagnosis (pre-HT smokers 80%, 
nonsmokers 76%). 
Although the HT patients in this study differed little from lung cancer patients in general as regards 
the proportion of cases that were inoperable or only palliatively operable (as also regarding survival), the 
frequency with which our HT patients underwent check-ups suggests that the disease may advance 
somewhat more rapidly in HT patients than in others; this idea is in keeping with a report that nonsmall-
cell lung cancer tends to be diagnosed at a later stage in organ transplant recipients than in the general 
population (28). On the other hand, the lung cancer screening in these check-ups will mostly have been 
based on chest X-rays, the sensitivity of which for this purpose is notoriously poor. The use of more 
sensitive techniques is thus desirable both for clarification of tumor aggressiveness and, of course, 
because of the better prognosis of cases diagnosed early enough to be operable, which has been noted in 
this study and by others (e.g. Anyanwu et al. (21), Bruschi et al. (26) or Padilla et al. (29)). In particular, 
in HT follow-up protocols it may be beneficial to replace chest X-rays with low-dose spiral computed 
tomography (21,26,27), at least on a trial basis. Although the proven sensitivity of spiral CT (The 
International Early Lung Cancer Action Program Investigators 2006) may be offset in the general 
population by poor specificity or overdiagnosis—the results of the US NCI National Lung Screening 
Trial are eagerly awaited—these drawbacks may be less significant in an immunosuppressed population 
such as HT patients. Recent advances in screening for biomarkers of lung cancer in sputum should also be 
borne in mind; see, for example, Xing et al. (30) and Varella-García et al. (31). 
The major limitations of this study derive firstly from there being no Spanish national cancer registry, 
which has forced us to use GLOBOCAN estimates for the incidence of lung cancer in the general 
population; and secondly from the quite coarse nature of the registry data. In particular, the SPHTTR has 
no staging information for the tumors it records; and although it distinguishes between pre-HT smokers 
and nonsmokers, it has no information on duration or intensity of smoking, or on date of cessation, or on 
post-HT smoking. 
In spite of the above limitations, we conclude that the incidence of lung cancer among HT patients is 
greater than in the general population, and that this is not due to a greater prevalence of smokers or 
former smokers among HT patients (although pre-HT smoking does increase risk). Incidence increases 
with age, and is greater among men than women. The prognosis is usually dismal due to late detection; 
early intervention following early detection multiplies the 2-year survival rate by more than four, 
suggesting that it may be beneficial to employ CT scans in the follow-up of HT patients. 
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